Questions Controls

PEDIATRICS ◽  
1981 ◽  
Vol 68 (6) ◽  
pp. 913-913
Author(s):  
Stephen F. Garrison
Keyword(s):  
Gestational Age ◽  
Statistical Difference ◽  
Control Group ◽  
Phase 2 ◽  
Double Blind ◽  
Control Subjects ◽  
Double Blind Control Study ◽  
Control Study ◽  
Patent Ductus ◽  
Indomethacin Treatment

In regard to the article, "Indomethacin Treatment for Symptomatic Patent Ductus Arteriorus: A Double-Blind Control Study" (Pediatrics 67:647, 1981), I feel that the study is invalidated because of poor controls. The authors state, "Despite randomization, however, in phase 2 the indomethacin-treated infants were significantly larger and more mature than the corrsponding control subjects, 1.39 ± 0.1 kg and 31.4 ± 0.5 weeks vs 1.1 ± 0.1 kg and 29 ± 0.4 weeks, respectively." A statistical difference of 2 weeks of gestational age could account for the increased morbidity and mortality of the control group.

Indomethacin Treatment for Symptomatic Patent Ductus Arteriosus: A Double-Blind Control Study

PEDIATRICS ◽  
1981 ◽  
Vol 67 (5) ◽  
pp. 647-652
Author(s):  
Ruth M. Yanagi ◽  
Allen Wilson ◽  
Edgar A. Newfeld ◽  
Kalim U. Aziz ◽  
Carl E. Hunt
Keyword(s):  
Patent Ductus Arteriosus ◽  
Phase 1 ◽  
Ductus Arteriosus ◽  
Control Group ◽  
Phase 2 ◽  
Closure Rate ◽  
Double Blind ◽  
Double Blind Control Study ◽  
Patent Ductus ◽  
Indomethacin Treatment

A double-blind control study was designed to determine the efficacy and safety of indomethacin treatment of patients with symptomatic patent ductus arteriosus. Infants with severe respiratory distress syndrome and symptomatic patent ductus arteriosus were eligible for this prospective study if the ratio of left atrial/aortic root diameter remained ≥ 1.3:1 following a 24-hour period of medical management. Thirty-nine eligible infants were randomly assigned to the control or indomethacin group and given 0.2 mg/kg of enteral indomethacin or placebo in a double-blind manner. Second and third doses were administered at 24-hour intervals in phase 1 (17 patients), and at eight-hour intervals in phase 2 (22 patients). The 75% patent ductus arteriosus closure rate with indomethacin treatment in phase 1 was not statistically significant due to a 44% spontaneous closure rate in the control group. In phase 2, however, 85% of the indomethacin group demonstrated patent ductus arteriosus closure vs only 11% in the matched control group (P .01). Although no indomethacin side effects occurred in phase 1, in phase 2 indomethacin administration was associated with minimal, but statistically significant, transient impaired renal function and, in three infants (23%), mild upper gastrointestinal bleeding. In summary, enteral administration of three 0.2 mg/kg indomethacin doses at eight-hour intervals thus appears to be a safe and effective alternative to surgical closure.

scholarly journals A comparative study on placebo and trenaxamic acid for the prophylaxis is of post-partum hemorrhage: a randomised double-blind control study

2019 ◽  
Vol 8 (3) ◽  
pp. 1143
Author(s):  
S. Parveen ◽  
G. Kesava Chandra ◽  
K. Ravindra Reddy ◽  
A. V. Kavya Sree ◽  
M. Varalakshmi ◽  
...  
Keyword(s):  
Blood Loss ◽  
Vaginal Delivery ◽  
Routine Care ◽  
Normal Vaginal Delivery ◽  
Control Group ◽  
Study Group ◽  
Double Blind ◽  
Average Blood Loss ◽  
Double Blind Control Study ◽  
Control Study

Background: Obstetric haemorrhage accounts for 20-25% of maternal mortality and morbidity. Anti-fibrinolytics are being widely used in field of surgery. It is also used to reduce heavy menstrual blood loss. The aim of this study was to analyse the effectiveness of TXA in reducing blood loss during normal vaginal delivery.Methods: The randomized double-blind control study was done in the Labour ward. It was conducted on 100 women undergoing Normal vaginal delivery. They were allocated to either Study or Control group by randomization. TXA was given during the Third stage of delivery in study group in addition to the routine care whereas the control group had routine care alone. Blood loss was measured in both groups by bag method.Results: The significant of reduction in blood loss calculated from placental delivery to 2hrs. 141.9 ml in study group versus 270.4 ml in control group. Among primi patients, the control group average blood loss was 325ml, the study group avg blood loss was 169ml. Among G2 patients, the control group average blood loss was 248.5ml. The study group average blood loss was 128.25ml. Among G3 patients, the control group average blood loss was 203ml, the study group average blood loss was 115ml.Conclusions: TXA significantly reduced the amount of blood loss during normal vaginal delivery. Thus, TXA can be used safely and effectively in subjects undergoing normal vaginal delivery.

JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study

2018 ◽  
Vol 68 ◽  
pp. S103 ◽  
Author(s):  
A.M. Diehl ◽  
S. Harrison ◽  
S. Caldwell ◽  
M. Rinella ◽  
A. Paredes ◽  
...  
Keyword(s):  
Nonalcoholic Steatohepatitis ◽  
Placebo Control ◽  
Phase 2 ◽  
Placebo Control Study ◽  
Double Blind ◽  
Control Study

scholarly journals Single bolus parecoxib attenuates sore throat after laryngeal microsurgery: A randomized double-blind control study

2014 ◽  
Vol 30 (11) ◽  
pp. 574-578 ◽  
Author(s):  
Hui-Fang Huang ◽  
Pi-Ying Chang ◽  
Yu-Chun Chen ◽  
Kuang-Yi Tseng ◽  
Hung-Te Hsu ◽  
...  
Keyword(s):  
Sore Throat ◽  
Double Blind ◽  
Single Bolus ◽  
Double Blind Control Study ◽  
Control Study

scholarly journals Amantadine Therapy for Fatigue in Multiple Sclerosis

1985 ◽  
Vol 12 (3) ◽  
pp. 251-254 ◽  
Author(s):  
T.J. Murray
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Marked Improvement ◽  
Double Blind ◽  
Moderate Improvement ◽  
Mild Improvement ◽  
Double Blind Control Study ◽  
Control Study

ABSTRACT:We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo. On amantadine 31% had marked improvement; 15.6% moderate improvement; 15.6% mild improvement; and 36.5%unchanged. On placebo, none noted marked improvement; one claimed moderate improvement on either amantadine or placebo. 18.7% reported mild improvement on placebo; and most of them had similar or more response to amantadine. No patient selected placebo over amantadine at the end of the trial. Overall improvement was seen in 62.5% of patients on amantadine and 21.8% on placebo. Additional experience up to two years suggests continued benefit but common and important side-effects.

scholarly journals Double-blind control study of low energy lazer treatment for chronic musculoskeltal pain

1991 ◽  
Vol 12 (Supplement) ◽  
pp. 256-258
Author(s):  
Ryoji Kayamori ◽  
Masahiro Mikami ◽  
Katuaki Takino
Keyword(s):  
Low Energy ◽  
Double Blind ◽  
Double Blind Control Study ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document